Status:

Red

Decision Date:

February 2024

Comments

RED: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer as per NICE TA944. NHSE commissioned (Decision - February 2024)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again